Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

Lilly CEO Sees Weight-loss Drugs Reaching About Half Of Potential Users At Peak

Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems ⁠and financial...

Restrictive Food Disorder Prevalence Overestimated

Avoidant/restrictive food intake disorder was inconsistently identified in patients with GI disorders, likely leading to overestimation of its prevalence.

‘Secret Shopper’ Study Finds Risks in Compounded GLP-1s

Study on compounded GLP-1s uncovers use of additives and questionable sterility practices, revealing legally ‘murky’ area.

M1 Variant Lowers APOL1 Kidney Disease Risk

Although APOL1 variants are linked to kidney disease risk, the presence of the M1 genetic variant appears to reduce that risk.

Weekend Catch-Up Sleep May Harm Glucose Control

A large NHANES analysis suggests that 7 hours of sleep may represent a metabolic sweet spot, whereas too little, too much, or excessive weekend catch-up sleep may worsen insulin resistance.

Microbiome May Predict Fiber-Induced Bloating

Few patients with bloating experience symptoms from fermentable fibers, with predictors including a higher baseline symptom burden and distinct gut microbiome patterns.

Todays Updates

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Todays Updates

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Latest News

Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems ⁠and financial...

Avoidant/restrictive food intake disorder was inconsistently identified in patients with GI disorders, likely leading to overestimation of its prevalence.

Study on compounded GLP-1s uncovers use of additives and questionable sterility practices, revealing legally ‘murky’ area.

Although APOL1 variants are linked to kidney disease risk, the presence of the M1 genetic variant appears to reduce that risk.

A large NHANES analysis suggests that 7 hours of sleep may represent a metabolic sweet spot, whereas too little, too much, or excessive weekend catch-up sleep may worsen insulin resistance.

Few patients with bloating experience symptoms from fermentable fibers, with predictors including a higher baseline symptom burden and distinct gut microbiome patterns.

News All Time

Managing Care When Gender-Affirming Therapy Is Limited

As access to gender-affirming care for minors narrows, clinicians are adapting — using nonhormonal options, stronger mental health support, and creative, patient-centered strategies.

Postmenopausal HRT Tied to Glaucoma Risk in Women

The use of postmenopausal hormone replacement therapy is associated with an increased risk for glaucoma in Finnish women aged 50 years or older, according to a recent nested case-control study.

Novo Nordisk Launches Wegovy Subscription Program

The telehealth platform program saves money for some self-pay patients, but experts express concerns about fragmentation of care.

Incretin-Based Drugs Show Superior Glycemic Profiles on CGM

Continuous glucose monitoring in the GRADE trial shows that incretin-based drugs such as sitagliptin and liraglutide produce the most stable glycemic profiles and show the lowest hypoglycemia risk.

Recent Depression Tied to Treatment Intensification in T2D

Patients with T2D who have a history of depression, especially a recent episode, are more likely to undergo earlier treatment intensification and insulin initiation than those who do not.

US FDA Weighs Broader Use Of Testosterone Therapy for Low Sex Drive in Men

The U.S. Food and Drug Administration is considering approving testosterone replacement therapy ⁠to treat low sex drive in men whose bodies do not produce enough of ⁠the...

Tirzepatide Best for Weight Loss in Adults Without T2D

High doses of the dual agonist tirzepatide appear to provide greater weight loss than other GLP-1s among adults with overweight or obesity who don’t have type 2 diabetes.

Knee Osteoarthritis Pain Relief Seen With Neurotrophin-3 Inhibition

A p75 neurotrophin receptor fusion protein reduces pain and improves function in patients with knee osteoarthritis across all tested doses and shows favorable safety outcomes in a phase 2 trial.

How Limited Is Evidence for Preventing Nephrolithiasis?

A systematic review finds limited evidence that selected drugs and hydration may reduce the risk for kidney stone recurrence.

Can Genes Affect GLP-1 Side Effects and Treatment Outcomes?

Two genetic variants may help explain differences in side effects and weight loss in patients taking GLP-1 drugs.

Lower Albumin Levels Linked to Fracture Risk in Older Women

Lower levels of serum albumin and lower values of a nutrition-related index are associated with a higher risk for fracture in older women.

Revolution Medicines' Experimental Cancer Pill Boosts Survival in Late-stage Study

Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live nearly twice as long as those treated ⁠with chemotherapy in a keenly anticipated...

SGLT2 Therapy Linked to Higher Ketoacidosis Risk in T2D

SGLT2 inhibitor therapy is linked to an increased risk for diabetic ketoacidosis in adults with T2D, particularly among those with elevated baseline A1c levels, a recent meta-analysis shows.

Fighting Outbreaks One Conversation at a Time

From Hackney to West Yorkshire, a GP and a public health researcher are tackling vaccine hesitancy by reaching the families mainstream messaging leaves behind.

Ginger Dietary Supplement May Ease GLP-1-Related Nausea

Primary endpoint didn’t reach significance, but secondary endpoints showed nausea reduction with herbal supplement from Dramamine maker.

FDA Requires Lilly to Conduct Post-marketing Studies for Obesity Pill

The ⁠U.S. Food and ⁠Drug Administration said ⁠Eli ‌Lilly is required to conduct post-marketing ‌trials to gauge risks ‌for ‌liver injury, cardiovascular ⁠events, ‌gastric...

Recommended News For You

Sickle Cell Disease Drug Pulled From Global Markets

Early cancer detection during pregnancy and the postpartum period may be aided by breast milk examination.

High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

Acupuncture may alleviate nocturia in men treated for prostate cancer

TikTok creators perform 'roles' when sharing their hereditary cancer stories, shaping the health information they share

Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?

Recommended Articles For You

Mastering Oncology RCM: Reducing Errors, Denials & Improving Billing Efficiency 

The Latest Advances in Glioblastoma Treatment and Prevention  

Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity 

Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chronic pain and poor sleep are troublesome bed partners.

2.

'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested

3.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

4.

Alkem introduces cetuximab under the trade name Cetuxa in India.

5.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

1.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

2.

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment

3.

The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery

4.

Understanding Melanoma: From Diagnosis to Healing and Excision in Denver

5.

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

2.

Navigating the Complexities of Ph Negative ALL - Part IX

3.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

4.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot